通脉养心丸干预冠心病PCI术后心肌重构:双盲随机对照试验方案
本研究为多中心、双盲、随机、安慰剂对照、平行组优效性试验,旨在验证通脉养心丸(TMYX)联合常规治疗是否干预冠心病PCI术后心肌重构与心功能不全。主要终点为左室舒张末期容积指数,次要终点包括中医证候评分、超声心动图、6分钟步行试验、西雅图心绞痛问卷、心脏磁共振、生物学指标、动态心电图及试验事件率,于基线及随机后4、8、12周评估。
要点
- 通脉养心丸联合常规治疗可能干预PCI术后心肌重构与心功能不全。
- 主要终点为左室舒张末期容积指数(左室舒张末期容积/体表面积)。
- 评估时间点为基线及随机后4、8、12周。
核心结论
- 通脉养心丸联合常规治疗将干预冠心病PCI术后心肌重构与心功能不全的发展。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照、平行组优效性试验。
- 参与者按1:1比例通过中心控制、计算机生成的简单随机化方案分组。
- 主要终点为左室舒张末期容积指数(左室舒张末期容积/体表面积)。
关键数值与推荐
- 在40%-56%的心肌梗死患者中出现心功能障碍,约25%-33%发展为心力衰竭。
- 次要复合结局包括中医证候评分、超声心动图结果、6分钟步行试验结果、西雅图心绞痛问卷评分、心脏磁共振成像结果、生物学指标、动态心电图结果及试验事件率。
- 评估在基线及随机后4、8、12周进行。
临床怎么用
- 本试验将为通脉养心丸在冠心病PCI术后常规治疗基础上干预心肌重构提供证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronary heart disease (CHD) has become a common cardiovascular disease that seriously threatens the health of people. As reperfusion in the early phase and drug therapy, especially percutaneous coronary intervention (PCI), have become widely used in the clinic, the mortality of acute myocardial infarction in the short term has been reduced significantly. In addition, in 40%-56% of patients who experience myocardial infarction, cardiac dysfunction occurs and about 25%-33% develop heart failure. METHODS: This study was designed as a multicenter, double-blind, randomized, placebo-controlled, parallel-group, superiority trial. Participants were randomly assigned in a 1:1 ratio through a centrally controlled, computer-generated, simple randomization schedule. The primary outcome was left ventricular end-diastolic volume index = left ventricular end-diastolic volume/body surface area. The combined secondary outcomes include traditional Chinese medicine syndrome score, echocardiogram results, 6-minute walk test results, Seattle Angina Questionnaire score, cardiac magnetic resonance imaging results, biological indicators, dynamic electrocardiogram results, and experiment event rate. Assessments will be performed at baseline and at 4, 8, and 12 weeks after randomization. DISCUSSION: This trial will demonstrate that the addition of a Tongmai Yangxin pill (TMYX) to conventional treatment will intervene in the development of cardiac remodeling and cardiac dysfunction. TRIAL REGISTRATION: This study was registered in the Chinese Clinical Trial Registry on 7 May 2019. The registration number is ChiCRT1900023023 (http://www.chictr.org.cn/showproj.aspx?proj=12370).
引用
- Wang Y, Wang X, Wang J, et al. Tongmai Yangxin intervening in myocardial remodeling after PCI for coronary heart disease: study protocol for a double-blind, randomized controlled trial. Trials. 2020. PMID: 32197640. doi:10.1186/s13063-020-4208-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。